Malaria researcher wins major award
Professor Brendan Crabb AC, Director and CEO of Burnet Institute, has received the 2019 GSK Award for Research Excellence for his research focused on finding the next generation of treatments and vaccines for malaria. His work has transformed how scientists explore malaria prevention and treatments globally.
Malaria is one of the most important health problems humans have ever faced. It is one of the leading causes of death and disease burden globally, with 1200 children dying of the disease every day.
Prof Crabb was involved in the technical breakthrough of DNA ‘transfection’ of the malaria parasite. Transfection is a powerful tool that enables scientists to manipulate the genome of the malaria parasite. By tweaking the parasite’s DNA, Prof Crabb and his team are working to discover which mutations are responsible for drug resistance and what parts can be targeted by new medicines and vaccines.
“There is probably no more impactful contribution to human development than ridding the world of malaria,” Prof Crabb said.
“The scale is unimaginable with around 3.2 billion people at risk of the disease.
“While malaria most significantly impacts the world’s poorest countries near the equator, this has a flow-on effect for Australia. Countries like Papua New Guinea and Indonesia are our neighbours, trading partners and popular travel destinations. We need to work collaboratively to help these countries deal with the burden of malaria. It will improve their health and drive greater security and prosperity for all,” he said.
The GSK Award for Research Excellence has been awarded since 1980 to recognise outstanding achievements in medical research with potential importance to human health. Prof Crabb said that winning the award highlights the power of local collaboration and brings greater awareness to the importance of combating malaria.
“Everything I’ve achieved has been done as part of a team. This award also recognises the efforts of my colleagues, teams, industry and patients. I am honoured to have received this award — especially as it draws attention to the fact that many of our human brothers and sisters still suffer enormously from malaria,” he said.
GSK Australia Medical Director Dr Andrew Weekes said GSK is proud to be supporting Australian researchers with this award, now in its 39th year.
“The work of Prof Crabb is testament to the impact home-grown research and innovation can have on a global scale. We are honoured to recognise research enabling further discoveries and better outcomes for people suffering from global health inequities,” Dr Weekes said.
Abcam has announced the successful completion of the acquisition of Expedeon's Proteomics and...
ISO 35001 defines the requirements and guidance for laboratories or any other organisation that...
Novartis is offering a US$250,000 prize to fund development of pioneering innovation with great...